Immune checkpoint inhibitor therapy for cancer treatment can give rise to a variety of adverse events. Here we report a male patient with metastatic melanoma who experienced life-threatening colitis and duodenitis following treatment with ipilimumab and nivolumab. The patient did not respond to the first three lines of immunosuppressive therapy (corticosteroids. infliximab. https://www.roneverhart.com/Craggy-Range-Sauvignon-Blanc-Te-Muna-Road-Vineyard-Martinborough-2022/